Literature DB >> 26658627

Uptake and Effectiveness of a Trivalent Inactivated Influenza Vaccine in Children in Urban and Rural Kenya, 2010 to 2012.

Mark A Katz1, Emmaculate Lebo, Gideon O Emukule, Nancy Otieno, Deborah L Caselton, Godfrey Bigogo, Henry Njuguna, Philip M Muthoka, Lilian W Waiboci, Marc-Alain Widdowson, Xiyan Xu, Moses K Njenga, Joshua A Mott, Robert F Breiman.   

Abstract

BACKGROUND: In Africa, recent surveillance has demonstrated a high burden of influenza, but influenza vaccine is rarely used. In Kenya, a country with a tropical climate, influenza has been shown to circulate year-round, like in other tropical countries.
METHODS: During 3 months in 2010 and 2011 and 2 months in 2012, the Kenya Medical Research Institute/Centers for Disease Control and Prevention-Kenya offered free injectable trivalent inactivated influenza vaccine to children 6 months to 10 years old in 2 resource-poor communities in Kenya-Kibera and Lwak (total population ~50,000). We conducted a case-control study to evaluate vaccine effectiveness (VE) in preventing laboratory-confirmed influenza associated with influenza-like illness and acute lower respiratory illness.
RESULTS: Of the approximately 18,000 eligible children, 41%, 48% and 51% received at least 1 vaccine in 2010, 2011 and 2012, respectively; 30%, 36% and 38% were fully vaccinated. VE among fully vaccinated children was 57% [95% confidence interval (CI): 29% to 74%] during a 6-month follow-up period, 39% (95% CI: 17% to 56%) during a 9-month follow-up period and 48% (95% CI: 32% to 61%) during a 12-month follow-up period. For the 12-month follow-up period, VE was statistically significant in children <5 years and in children 5 to <10 years old (50% and 46%, respectively).
CONCLUSIONS: In Kenya, parents of nearly half of the eligible children <10 years old chose to get their children vaccinated with a free influenza vaccine. During a 12-month follow-up period, the vaccine was moderately effective in preventing medically attended influenza-associated respiratory illness.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26658627     DOI: 10.1097/INF.0000000000001035

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study.

Authors:  Shuo Feng; Susan S Chiu; Eunice L Y Chan; Mike Y W Kwan; Joshua S C Wong; Chi-Wai Leung; Yiu Chung Lau; Sheena G Sullivan; J S Malik Peiris; Benjamin J Cowling
Journal:  Lancet Respir Med       Date:  2018-11-12       Impact factor: 30.700

2.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

3.  Building laboratory capacity to detect and characterize pathogens of public and global health security concern in Kenya.

Authors:  Elizabeth Hunsperger; Bonventure Juma; Clayton Onyango; John B Ochieng; Victor Omballa; Barry S Fields; M Kariuki Njenga; Jane Mwangi; Godfrey Bigogo; Richard Omore; Nancy Otieno; Sandra S Chaves; Peninah Munyua; Daniel Macharia Njau; Jennifer Verani; Sara Lowther; Robert F Breiman; Joel M Montgomery; Kevin M De Cock; Marc-Alain Widdowson
Journal:  BMC Public Health       Date:  2019-05-10       Impact factor: 3.295

4.  The epidemiology of seasonal influenza after the 2009 influenza pandemic in Africa: a systematic review.

Authors:  Adamou Lagare; Soatiana Rajatonirina; Jean Testa; Saidou Mamadou
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

5.  Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling.

Authors:  Jeanette Dawa; Gideon O Emukule; Edwine Barasa; Marc Alain Widdowson; Omu Anzala; Edwin van Leeuwen; Marc Baguelin; Sandra S Chaves; Rosalind M Eggo
Journal:  BMC Med       Date:  2020-08-20       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.